A Companion diagnosis (CDx) refers to a medical device or test that provides essential information for the safe and effective use of a specific biological product, typically associated with highly personalized or targeted pharmacological treatments. Its primary function is to assist the healthcare professional in assessing whether the benefits of a medication or treatment for a patient will outweigh potential side effects or serious risks.
These specific tests have been in use since the mid-1990s, and the majority, around 90%, are employed in the field of oncological treatments. Additionally, other types of complementary diagnoses include a complete blood count (CBC), which is mandatory before administering clozapine, a medication used in the treatment of severe
Companion Diagnostics (CDx) play a crucial role in biomarker detection for several fundamental reasons:
1. Treatment personalizatio
Biomarkers are biological indicators associated with certain diseases or conditions. CDx enable the specific identification of these biomarkers, facilitating the personalization of treatments. By knowing a patient's unique biomarkers, doctors can select therapies that are more effective for their specific condition, maximizing the likelihood of treatment success.
2. Avoiding ineffective treatments
The precise identification of biomarkers through CDx helps avoid treatments that might not be effective for a particular patient. This not only reduces the risk of unnecessary side effects but also optimizes the use of medical resources by directing therapies towards those more likely to be beneficial.
3. Improving treatment efficacy
By focusing on specific biomarkers, this diagnostics improve treatment efficacy by ensuring that selected therapies align with the unique molecular and genetic characteristics of each patient. This leads to more precise and personalized healthcare.
4. Disease diagnosis and stratification
In many cases, biomarkers indicate specific subtypes of diseases. Companion Diagnostics not only aid in the early identification of diseases but also allow the stratification of patients into more homogeneous groups based on the molecular characteristics of their diseases. This is particularly crucial in fields like oncology.
5. Facilitating research and drug development
Companion Diagnostics play a vital role in clinical research and drug development. By identifying specific biomarkers, more precise clinical trials can be conducted, accelerating the drug approval process and enabling the introduction of more effective therapies to the market.
6. Optimizing healthcare resources
By avoiding ineffective treatments and providing more specific approaches, CDx contribute to the optimization of resources in the healthcare system. This can lead to more efficient resource allocation and reduce costs associated with treatments that may not benefit the patient.
In summary, are essential for biomarker detection because they enable more precise, personalized, and effective medicine, improving both the diagnostic process and the treatment of various diseases.